Table 3 Proportion of doses being selected as ED90 of Bayesian Emax and NDLM model at different dose response curves in the Half Adaptive design settings (Scenario 3)
Dose Level (mg/kg) | ||||||
|---|---|---|---|---|---|---|
0.03 | 0.3 | 3 | 10 | 20 | 30 | |
Bayesian Emax Model | ||||||
Proportion of doses being selected as ED90 | ||||||
Flat placebo like Curvea | 0% | 0% | 0% | 0% | 38% | 0% |
Emax like Curve | 0% | 0% | 0% | 0% | 89% | 11% |
Log Linear Curve | 0% | 0% | 0% | 0% | 81% | 19% |
U-Shape Curvea | 0% | 0% | 0% | 0% | 64% | 0% |
Bayesian NDLM Model | ||||||
Proportion of doses being selected as ED90 | ||||||
Flat placebo like curve | 16% | 17% | 14% | 14% | 11% | 12% |
Emax like Curve | 1% | 1% | 14% | 25% | 35% | 26% |
Log Linear Curve | 1% | 1% | 5% | 11% | 29% | 54% |
U-Shape Curve | 2% | 42% | 48% | 5% | 2% | 0% |